Latest News and Press Releases

Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, announced today the completion of the equity...

REYKJAVIK, Iceland, Feb. 10, 2023 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide,...

Partners Alvotech and STADA have marketing authorization application (MAA) for ustekinumab accepted for filing by the European Medicines Agency (EMA) EMA opinion on AVT04 could come as soon as the...

Álit Evrópsku lyfjastofnunarinnar (EMA) gæti legið fyrir á síðari helmingi ársins 2023Frumlyfið Stelara® (ustekinumab) er gefið sjúklingum með ýmsa bólgusjúkdóma Alvotech (NASDAQ: ALVO) og alþjóðlega...

Partners Alvotech and STADA have marketing authorization application (MAA) for ustekinumab accepted for filing by the European Medicines Agency (EMA) EMA opinion on AVT04 could come as soon as...

Advanz Pharma will commercialize AVT23, a proposed biosimilar to Xolair® (omalizumab) in the European Economic Area, UK, Switzerland, Canada, Australia, and New Zealand REYKJAVIK, Iceland,...

Advanz Pharma will commercialize AVT23, a proposed biosimilar to Xolair® (omalizumab) in the European Economic Area, UK, Switzerland, Canada, Australia, and New Zealand Alvotech (NASDAQ: ALVO), a...

Advanz Pharma fær rétt til að markaðssetja AVT23, fyrirhugaða líftæknilyfjahliðstæðu við Xolair® (omalizumab) á Evrópska efnahagssvæðinu, í Bretlandi, Sviss, Kanada, Ástralíu og á Nýja Sjálandi ...

 AVT02 as Simlandi™ is the first biosimilar approved under the strategic partnership between Alvotech and Bioventure REYKJAVIK, Iceland and DUBAI, United Arab Emirates, Jan. 24, 2023 (GLOBE...

AVT02 as Simlandi™ is the first biosimilar approved under the strategic partnership between Alvotech and Bioventure Alvotech (NASDAQ: ALVO) and Bioventure, a wholly owned subsidiary of GlobalOne...